• FOXM1–ERα ceRNA Network in Female Lung Adenocarcinoma: Bioma

  2026-06-05

  This study identifies a novel competitive endogenous RNA (ceRNA) network involving FOXM1, miR-204-5p, and estrogen receptor 1 (ERα) in female lung adenocarcinoma. By integrating multi-omics data and molecular validation, it reveals mechanistic links between transcriptional regulation, estrogen receptor signaling, and immune response, offering new avenues for biomarker-guided research and potential therapeutic strategies.

• A 83-01 (ALK-5 Inhibitor): Precision Control of Organoid Ste

  2026-06-05

  Explore how A 83-01, a selective ALK-5 inhibitor, enables unprecedented control over stem cell self-renewal and differentiation in organoid research. This article reveals new assay strategies and practical protocols grounded in recent breakthroughs on tunable human intestinal organoid systems.

• MLN4924 HCl Salt: Optimizing NEDD8-Activating Enzyme Inhibit

  2026-06-04

  MLN4924 HCl salt empowers researchers with selective, potent inhibition of the neddylation pathway, advancing studies in cancer biology and viral immunology. This guide spotlights protocol enhancements, troubleshooting tactics, and real-world use-cases that maximize the scientific impact of this NEDD8-activating enzyme inhibitor.

• Primidone-Mediated TRPM3 Inhibition for Adenomyosis Relief

  2026-06-04

  This study identifies overexpression of TRP channels in adenomyosis and demonstrates that Primidone, via TRPM3 inhibition, significantly reduces pain and myometrial infiltration in a mouse model. The findings outline a non-hormonal, mechanistically targeted approach for managing adenomyosis symptoms and provide a foundation for future research on TRP channel modulation in gynecological disorders.

• Dissecting Drug Response Metrics in Cancer: Insights from In

  2026-06-03

  Schwartz's dissertation redefines how in vitro cancer drug responses are evaluated by distinguishing between proliferative arrest and cell death using refined viability metrics. These methodological advances highlight the need for nuanced analysis of drug effects, informing more accurate preclinical assessment and translational research.

• n-Alkyl Modified Copper Ionophores Induce Cuproptosis in Can

  2026-06-03

  This study introduces a rational approach to designing copper ionophores with varying n-alkyl chain lengths for controlled induction of cuproptosis in cancer cells. The work identifies C6 as a lead compound with high efficacy against triple-negative breast cancer, providing new insights for metal homeostasis-driven anticancer strategies.

• O-GlcNAcylation Drives Wnt-Induced Glycolysis and Bone Forma

  2026-06-02

  This study uncovers how O-GlcNAcylation is indispensable for Wnt-stimulated bone formation, acting through metabolic rewiring of osteoblasts. The findings highlight distinct temporal mechanisms by which Wnt3a enhances O-GlcNAcylation, ultimately stabilizing PDK1 and promoting aerobic glycolysis to support osteogenesis.

• GM 6001 (Galardin): Broad Spectrum Matrix Metalloproteinase

  2026-06-02

  GM 6001 (Galardin) is a potent, broad-spectrum inhibitor of matrix metalloproteinases (MMPs), offering sub-nanomolar affinity for key MMP isoforms. Its use enables precise control of extracellular matrix remodeling in diverse research contexts, including tissue repair and cancer biology. APExBIO supplies GM 6001 (SKU A4050) as a research-grade solid for advanced MMP-related assays.

• PPP1R3G/PP1γ Regulation of RIPK1 Drives Cell Death Pathways

  2026-06-01

  This study uncovers how PPP1R3G and PP1γ dephosphorylate RIPK1, controlling its kinase activation and thereby promoting apoptosis and necroptosis. The findings refine our understanding of inflammation-linked cell death and provide a foundation for precise experimental modulation of these pathways.

• YM-155 Hydrochloride: Survivin Inhibitor for Tumor Regressio

  2026-06-01

  YM-155 hydrochloride stands out as a nanomolar-potency survivin inhibitor, enabling selective targeting of apoptosis pathways in diverse cancer models. This article bridges novel in vitro drug response metrics with actionable workflows, empowering researchers to optimize experimental fidelity and advance preclinical oncology studies.

• PKM2 Inhibitor (Compound 3k): A Paradigm Shift in Cancer Met

  2026-05-31

  This article explores the mechanistic foundation and translational promise of PKM2 inhibitor (compound 3k) as an advanced tool for disrupting cancer cell metabolism. By integrating new mechanistic insights—specifically the role of pyruvate kinase M2 in immunometabolic reprogramming and tumor biology—with cutting-edge preclinical evidence, it provides actionable guidance for translational researchers. The discussion bridges oncology and immunometabolism, highlights the unique positioning of compound 3k from APExBIO, and outlines protocol parameters and strategic considerations for implementing this potent PKM2 inhibitor in research workflows.

• Pexidartinib (PLX3397): Enhancing CSF1R-Mediated Tumor Macro

  2026-05-30

  Pexidartinib (PLX3397) streamlines tumor microenvironment research by enabling precise CSF1R signaling inhibition and robust macrophage modulation. This article provides step-by-step workflows, advanced use-case insights, and actionable troubleshooting—empowering oncology researchers to maximize reproducibility and translational impact.

• AMPK Suppresses, Rather Than Triggers, ULK1-Dependent Autoph

  2026-05-29

  This study redefines the canonical model of energy stress-induced autophagy by demonstrating that AMPK inhibits, rather than activates, ULK1 kinase. The findings reshape our understanding of autophagy regulation under metabolic stress and have practical implications for dissecting autophagy pathways using selective ULK1 kinase inhibitors.

• Pexidartinib (PLX3397): Selective CSF1R Inhibition in Cancer

  2026-05-29

  Pexidartinib (PLX3397) is a potent, orally bioavailable small molecule inhibitor targeting CSF1R, enabling precise modulation of tumor-associated macrophages in cancer research. Its nanomolar inhibition of CSF1R signaling induces anti-tumor apoptosis and supports reproducible, translational workflows. APExBIO supplies validated reagent-grade Pexidartinib for preclinical studies.

• TH287 MTH1 Inhibitor: Redefining Oxidative DNA Damage Resear

  2026-05-28

  Explore how TH287, a potent MTH1 inhibitor, is revolutionizing oxidative stress-induced DNA damage and radiosensitization studies. This article uncovers mechanistic insights and protocol optimizations for advanced cancer biology applications.

743 records 16/50 page Previous Next First page 上5页 1617181920 下5页 Last page